Human T-Lymphotropic Virus Type 1 (HTLV-1) and Regulatory T Cells in HTLV-1-Associated Neuroinflammatory Disease by Araya, Natsumi et al.
Viruses 2011, 3, 1532-1548; doi:10.3390/v3091532 
 
viruses
ISSN 1999-4915 
www.mdpi.com/journal/viruses 
Review 
Human T-Lymphotropic Virus Type 1 (HTLV-1) and 
Regulatory T Cells in HTLV-1-Associated  
Neuroinflammatory Disease 
Natsumi Araya 
1, Tomoo Sato 
1, Naoko Yagishita 
1, Hitoshi Ando 
1, Atae Utsunomiya 
2,  
Steven Jacobson 
3 and Yoshihisa Yamano 
1,* 
1  Department of Rare Diseases Research, Institute of Medical Science, School of Medicine, 
St. Marianna University, Kawasaki 216-8511, Japan; E-Mails: araya@marianna-u.ac.jp (N.A.); 
tomoo@marianna-u.ac.jp (T.S.); yagi@marianna-u.ac.jp (N.Y.); hando@marianna-u.ac.jp (H.A.) 
2  Department of Hematology, Imamura Bun-in Hospital, Kagoshima 890-0064, Japan;  
E-Mail: autsunomiya@jiaikai.jp 
3  Viral Immunology Section, Neuroimmunology Branch, National Institute of Neurological Disorders 
and Stroke, National Institutes of Health, Bethesda, MD 20892, USA;  
E-Mail: jacobsons@ninds.nih.gov 
*  Author to whom correspondence should be addressed; E-Mail: yyamano@marianna-u.ac.jp;  
Tel.: +81-44-977-8111; Fax: +81-44-977-9772. 
Received: 2 June 2011; in revised form: 13 August 2011 / Accepted: 16 August 2011 /  
Published: 25 August 2011 
 
Abstract: Human T-lymphotropic virus type 1 (HTLV-1) is a retrovirus that is the 
causative agent of adult T cell leukemia/lymphoma (ATL) and associated with multiorgan 
inflammatory disorders, including HTLV-1-associated myelopathy/tropical spastic 
paraparesis (HAM/TSP) and uveitis. HTLV-1-infected T cells have been hypothesized to 
contribute to the development of these disorders, although the precise mechanisms are not 
well understood. HTLV-1 primarily infects CD4
+ T helper (Th) cells that play a central 
role in adaptive immune responses. Based on their functions, patterns of cytokine 
secretion, and expression of specific transcription factors and chemokine receptors, Th 
cells that are differentiated from naïve CD4
+ T cells are classified into four major lineages: 
Th1, Th2, Th17, and T regulatory (Treg) cells. The CD4
+CD25
+CCR4
+ T cell population, 
which consists primarily of suppressive T cell subsets, such as the Treg and Th2 subsets in 
healthy individuals, is the predominant viral reservoir of HTLV-1 in both ATL and 
HAM/TSP patients. Interestingly, CD4
+CD25
+CCR4
+ T cells become Th1-like cells in 
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HAM/TSP patients, as evidenced by their overproduction of IFN-γ, suggesting that HTLV-1 
may intracellularly induce T cell plasticity from Treg to IFN-γ
+ T cells. This review 
examines the recent research into the association between HTLV-1 and Treg cells that has 
greatly enhanced understanding of the pathogenic mechanisms underlying immune 
dysregulation in HTLV-1-associated neuroinflammatory disease. 
Keywords: HTLV-1; HAM/TSP; ATL; CD4
+CD25
+CCR4
+ T cell; regulatory T cell; 
exFoxp3
+ cell; inflammation; immune-dysfunction 
 
1. Introduction 
Human T-lymphotropic virus type 1 (HTLV-1) is a retrovirus associated with chronic, persistent 
infection of human T cells. HTLV-1 infection is endemic in Japan, the Caribbean, and part of South 
America, Africa, the Middle East, and Melanesia [1]. Studies conducted in HTLV-1 endemic areas 
have demonstrated that HTLV-1 infection is associated with a variety of human diseases, including  
an aggressive mature T cell malignancy termed adult T-cell leukemia (ATL) [2], which is defined  
as neoplastic growth of HTLV-1-infected T cells. HTLV-1 is also associated with non-neoplastic 
inflammatory conditions such as HTLV-1-associated myelopathy/tropical spastic paraparesis 
(HAM/TSP) [3,4], uveitis [5], Sjögren syndrome [6], bronchoalveolitis, arthritis [7], and polymyositis [8], 
where high tissue concentrations of HTLV-1 infected T lymphocytes have been observed. Importantly, 
some patients have more than one of these HTLV-1-associated inflammatory conditions [9]. 
Although HTLV-1-associated disorders have been extensively studied, the exact mechanism by 
which HTLV-1 induces these inflammatory conditions is not completely understood. The proviral load 
of HTLV-1 may contribute to development of HTLV-1-associated inflammatory conditions, since the 
number of HTLV-1-infected T cells circulating in the peripheral blood is higher in patients with 
HAM/TSP than in asymptomatic HTLV-1-infected individuals [10,11], and is even higher in the 
cerebrospinal fluid of patients with HAM/TSP [12]. In HAM/TSP patients, the proviral load correlates 
with not only the percentage of activated CD4
+ T cells but also with that of HTLV-1-specific CD8
+ 
cytotoxic T lymphocytes (CTLs) [11,13]. These HTLV-1-specific CTLs produce various cytokines, 
such as IFN-γ and TNF-α, that may suppress viral replication and kill infected cells and/or promote 
bystander activation and killing of nearby resident cells in the central nervous system (CNS) [14–17]. 
In addition, increased viral expression, particularly of the transactivating viral gene encoding HTLV-1 
Tax, has also been hypothesized to play a role in HTLV-1 disease progression [11,12]. Transgenic 
mice expressing HTLV-1 Tax develop an inflammatory arthropathy [18], and transgenic rats 
expressing HTLV-1 env-pX develop destructive arthropathy, Sjögren syndrome, vasculitis, and 
polymyositis [19]. These findings support the hypothesis that HTLV-1 tax is one of the exogenous 
retrovirus genes responsible for immune dysregulation. 
HTLV-1 Tax is a transactivator/oncoprotein that has potent effects on infected T cells, including 
activation of nuclear factor(NF)-κB [20] with subsequent enhancement of cell activation and 
proliferation and expression of various cellular genes, such as IL-2 [21], the α-chain of the IL-2 
receptor (IL-2Rα) [22], IL-15 [23], and IL-15Rα [24]. Such virus-induced intracellular activation may Viruses 2011, 3                  
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directly contributes to T cell activation and the ex vivo T cell proliferation observed in patients with 
HAM/TSP [25]. These findings suggest that invasion by HTLV-1-infected T cells, together with viral 
gene expression and cellular-signaling mechanisms, trigger a strong virus-specific immune response 
and increased proinflammatory cytokine production, leading to CNS inflammation and autologous 
tissue damage. However, the precise mechanisms underlying the induction of immune activation by 
HTLV-1-infected T cells are not well understood. 
2. HTLV-1 and Regulatory T Cells 
The recent discovery of regulatory T cells (Treg cells) has generated new opportunities for and 
increased interest in elucidating the above mentioned mechanisms. In healthy individuals, the Treg 
cells, a subset of CD4
+CD25
+ T cells, play a key role in maintaining immune system homeostasis by 
suppressing the proliferation of and cytokine production by pathogenic T cells [26]. Although Treg 
cells are phenotypically similar to activated T cells, they can be identified ex vivo by their intracellular 
expression of the transcriptional regulator Foxp3 [27], which is critical in the development and 
functioning of Treg cells in both mice and humans. Significant reductions in Foxp3 expression 
and/or Treg cell function have been observed in patients with several types of human autoimmune 
diseases [28], suggesting that defects in Foxp3 expression and/or Treg functioning may precipitate loss 
of immunological tolerance. CD4
+CD25
+ T cells are also the predominant viral reservoir in the 
peripheral blood of HTLV-1-infected individuals [29]. Recently, significant reductions in Foxp3 
expression and Treg cell function have been observed in CD4
+CD25
+ T cells from patients 
with HAM/TSP [30–34]. Furthermore, decreased expression levels of CTL antigen-4 (CTLA-4), a 
Treg-associated immune-suppressive molecule, and glucocorticoid-induced tumor necrosis factor 
receptor-related protein (GITR) have also been observed on the CD4
+CD25
+ T cells of HAM/TSP 
patients [30,34]. Notably, overexpression of HTLV-1 Tax has been observed to reduce Foxp3 
expression and inhibit the suppressive function of Treg cells in vitro [30]. Furthermore, because of a 
Tax-induced defect in TGF-β signaling, Foxp3 expression was decreased
 and Treg functions were 
impaired in
  patients with HAM/TSP [35]. Recently, significantly decreased numbers of 
CD4
+CD25
+Foxp3
+ Treg cells were observed in transgenic mice expressing HTLV-1 Tax that develop 
an inflammatory arthropathy [36]. In addition, increased viral expression of the HTLV-1 bZIP factor 
(HBZ)  gene encoding the minus strand of HTLV-1 has also been suggested to play a role   
in HTLV-1 disease progression [37], and CD4
+Foxp3
+ Treg cells in HBZ transgenic mice were 
functionally impaired [38]. These findings indicate that HTLV-1-induced dysfunctioning of 
CD4
+CD25
+ Treg cells may be one of the mechanisms underlying the induction of immune activation 
by HTLV-1-infected T cells.  
In contrast to the decreased expression of Foxp3 in CD4
+CD25
+ T cells observed in HAM/TSP 
patients [30–34], most CD4
+CD25
+ ATL cells have been shown to express Foxp3 in patients with  
ATL [39,40]. Therefore, it has been hypothesized that ATL cells may be derived from Treg cells [41]. 
Interestingly, some ATL cells exhibit immunosuppressive functions similar to those of Treg cells, 
which may contribute to clinically observed cellular immunodeficiency in ATL patients [41–43], 
although some of these ATL cells lose this regulatory function [44]. Viruses 2011, 3                  
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3. HTLV-1 and CD4
+CD25
+CCR4
+ T Cells 
Although HTLV-1 has been reported to infect a number of cell types both in vitro and  
in vivo [29,45–49], CD4
+ Th cells, which play a central role in adaptive immune responses, are the 
predominant viral reservoir in the peripheral blood [50]. To understand the effects of HTLV-1 
infection on the functioning of CD4
+ Th cells, it is necessary to discover if, and if so which of the Th 
subpopulations is preferentially infected with HTLV-1. Based on their functions, patterns of cytokine 
secretion, and expression of specific transcription factors and chemokine receptors, CD4
+ Th cells, 
which are differentiated from naïve CD4
+ T cells, are classified into four major lineages: Th1, Th2, 
Th17, and Treg cells (Figure 1).  
Figure 1. T cell subsets of CD4
+ T helper cells. Th cells are differentiated from naïve 
CD4
+ T cells into 4 major lineages: Th1, Th2, Th17, and T-regulatory (Treg) cells. Each 
Th subset exhibits characteristic functions, patterns of cytokine secretion, and expression 
of specific chemokine receptors.  
 
 
The chemokine receptor CCR4 has recently been found to be expressed on HTLV-1-infected 
leukemia cells in ATL patients [51]. Because CCR4 is known to be selectively expressed on Treg 
and Th2 cells [51–53] (Figure 1) and because most ATL cells express high levels of Foxp3, it has 
been  hypothesized that ATL cells may be derived from Treg cells [41]. Although it has been Viruses 2011, 3                  
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demonstrated that CD4
+CD25
+ T cells in HAM/TSP patients exhibit reduced Foxp3 expression and 
Treg suppression [30–33] and that HTLV-1-infected CD4
+ T cells in HAM/TSP patients produce Th1 
cytokines (IFN-γ) [16,30], it has also been observed that CCR4 selectively overexpresses on 
HTLV-1-infected T cells in HAM/TSP patients [54]. Furthermore, the majority of CD4
+CD25
+CCR4
+ 
T cells have been found to be infected with HTLV-1 and this T cell subset has increased numbers in 
HAM/TSP patients [54]. Thus, CD4
+CD25
+CCR4
+ T cells are a major reservoir of HTLV-1-infected T 
cells, which are increased in numbers in both HAM/TSP and ATL patients. 
4. HTLV-1 and Foxp3
–CD4
+CD25
+CCR4
+ T Cells  
Although CCR4 is known to be selectively expressed on Treg and Th2 cells in healthy individuals, 
more detailed flow cytometric analysis of Foxp3 expression in CD4
+CD25
+CCR4
+ T cells of 
HAM/TSP patients demonstrated that the frequency of the Foxp3
– population was greatly increased in 
CD4
+CD25
+CCR4
+ T cells [54]. Moreover, analysis of proinflammatory cytokine expression in this 
Foxp3
–CD4
+CD25
+CCR4
+ T cell subset demonstrated that these cells uniquely produced multiple 
proinflammatory cytokines such as IL-2, IL-17, and few IFN-γ in healthy individuals while 
Foxp3
+CD4
+CD25
+CCR4
+ T cells (Treg cells) did not. Furthermore, it was demonstrated that 
HAM/TSP patients had only few Foxp3
+CD4
+CD25
+CCR4
+ T cells that did not produce such 
cytokines [54]. The Foxp3
–CD4
+CD25
+CCR4
+ T cells in HAM/TSP were greater in number and 
overproduced IFN-γ [54]. Further, the proportion of these IFN-γ-producing Foxp3
–CD4
+CD25
+CCR4
+ 
T cells may have a functional consequence, since the presence of this subpopulation could be 
correlated with disease activity and severity of HAM/TSP in vivo [54]. Thus, in a CD4
+CD25
+CCR4
+ 
T cell population that mainly consists of suppressive T cell subsets such as Treg and Th2 under healthy 
conditions, IFN-γ-producing Foxp3
–CD4
+CD25
+CCR4
+ T cells, rarely encountered in healthy 
individuals, were increased in number and overproduced IFN-γ in HAM/TSP patients (Figure 2). We 
therefore propose to call this IFN-γ
+Foxp3
–CD4
+CD25
+CCR4
+ T cell subset THAM cells. Interestingly, 
increased numbers of Foxp3
lowCD4
+CD25
+ memory
 T cells, which have cytokine secretion patterns 
similar to those of THAM cells, have recently been observed in patients with active systemic lupus 
erythematosus (SLE) [55]. Therefore, it would be of interest to build on this finding by confirming 
whether this newly defined unique T cell subset, which has been observed in both HAM/TSP and SLE 
patients, is found in both these patient groups and can be functionally deregulated in other 
immunological diseases. 
Although most CD4
+CD25
+CCR4
+ T cells are infected with HTLV-1 in both HAM/TSP and 
ATL  patients [54,56], the ratio of THAM cells (CCR4
+Foxp3
– with IFN-γ production) to Treg 
cells (CCR4
+Foxp3
+ with no cytokine production) in the CD4
+CD25
+CCR4
+ T cell subset has 
been found to be high in HAM/TSP patients but low in ATL patients [54]. This differential THAM/Treg 
ratio in HTLV-1-infected T cells may be associated with the differential immune responses observed 
between HAM/TSP and ATL patients (Figure 3). ATL patients tend to have very low numbers 
of Tax-specific  CD8
+ T cells in peripheral blood mononuclear cells (PBMCs) and to develop 
opportunistic infections [57,58], while HAM/TSP patients tend to have high numbers of Tax-specific 
CD8
+ CTLs [11,12,14,59]. As CD4
+CD25
+ T cells with high levels of Foxp3 expression have been 
reported to have an immunosuppressive function in ATL patients [41–43], the increased number of Viruses 2011, 3                  
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CD4
+CD25
+CCR4
+ leukemia T cells with Treg functions observed in ATL patients may contribute 
to  their clinically observed cellular immunodeficiency. However, HAM/TSP patients show very 
high cellular and humoral immune responses, such as high proportions of Tax-specific CD8
+ T cells, 
as well as cytomegalovirus (CMV)-specific CD8
+ T cells in the PBMCs [14,33]; high antibody   
titer to  HTLV-1 [9]; and increased production of proinflammatory cytokines, such as IL-12 and   
IFN-γ [60]. It  has been reported that CD4
+CD25
+ T cells with low expression of Foxp3 [30]   
and HTLV-1  Tax-expressing Foxp3
+ Treg cells [61] extracted from HAM/TSP patients exhibit 
defective immunosuppressive functioning. Moreover, it has been demonstrated that HTLV-1-infected 
IFN-γ-overproducing CD4
+CD25
+CCR4
+Foxp3
– T cells (THAM cells) increase in number in HAM/TSP 
patients, and their levels can be correlated with disease severity [54]. Thus, CD4
+CD25
+CCR4
+ T cells 
with increased proinflammatory functioning, together with a defective Treg compartment [30–33,54], 
may overcome the regulatory effect of HTLV-1-uninfected Treg cells [61] and at least partly account 
for the heightened immune response observed in HAM/TSP patients. Collectively, these observations 
support the hypothesis that an imbalance in the THAM/Treg ratio in HTLV-1-infected 
CD4
+CD25
+CCR4
+ T cells is an important contributing factor in the immunological differences in host 
immune response observed between HAM/TSP and ATL patients (Figure 3). 
Figure 2. Cellular components of CD4
+CD25
+CCR4
+ T cells in healthy donors and 
HAM/TSP patients. In healthy donors, the CD4
+CD25
+CCR4
+ T cell population   
primarily consists of suppressive T cell subsets, such as Treg and Th2, whereas that of  
HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients consists 
of an increased number of IFN-γ-producing Foxp3
–CD4
+CD25
+CCR4
+ T cells (THAM cells). 
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Figure 3. Differential immune responses and THAM/Treg ratios in CD4
+CD25
+CCR4
+ T 
cells in HAM/TSP and adult T cell leukemia/lymphoma (ATL) patients.  
 
 
5. Increased Numbers of CD4
+Foxp3
+ Cells in HAM/TSP Patients 
Recently, it has been reported that the number of CD4
+Foxp3
+ cells increases in HTLV-1-infected 
asymptomatic carriers, and is even higher in patients with HAM/TSP [61]. Although this report 
initially appears to conflict with the observations described above, it may not. In contrast to the 
decreased number of CD4
+ T cells in patients with human immunodeficiency virus (HIV) infection, 
the number of HTLV-1 infected CD4
+ T cells—most of which are CD4+CD25+CCR4+ T cells—in 
HAM/TSP patients is greatly increased. Therefore, although the percentage of Foxp3
+ cells among the 
CD4
+CD25
+CCR4
+ T cells is lower, the overall number of CD4
+Foxp3
+ cells in HAM/TSP patients 
may be higher than that in healthy donors (Figure 4). Indeed, when we analyzed the number of Foxp3
+ 
cells in healthy donors and HAM/TSP patients, we found it to be nearly equivalent between the two 
groups or slightly higher in HAM/TSP patients [54]. This difference (from slightly high to higher) 
would depend on the number of HTLV-1-infected CD4
+ T cells in the samples tested. Importantly, 
Toulza et al. demonstrated that the rate of CTL-mediated lysis was negatively correlated with the 
number of HTLV-1-Tax
¯CD4
+Foxp3
+ cells, but not with the number of Tax
+CD4
+Foxp3
+ cells [61], 
again suggesting that HTLV-1-infected Treg cells lose their regulatory function, while   
HTLV-1-uninfected Treg cells contribute substantially to immune control of HTLV-1 infection. Viruses 2011, 3                  
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Figure 4. Scheme of proportion of each cellular component in CD4
+CD25
+CCR4
+ T cells 
of healthy donors, asymptomatic carriers (AC), and patients with HAM/TSP or ATL. 
Although the proportion of Foxp3
+ cells among the CD4
+CD25
+CCR4
+ T cells is lower in 
HAM/TSP patients, the overall number of CD4
+Foxp3
+ cells in HAM/TSP patients is 
higher than that in healthy donors. In ATL patients, the majority of CD4
+CD25
+CCR4
+ T 
cells are Foxp3
+ cells.  
 
6. Does the THAM Cell Population Include exFoxp3
+ Cells? 
According to Hieshima et al.’s recent delineation of the molecular mechanism underlying HTLV-1 
tropism to CCR4
+CD4
+ T cells [60], HTLV-1 Tax does not induce expression of CCR4, but Tax does 
induce expression of CCL22, which is the ligand for CCR4. Therefore, HTLV-1-infected T cells 
produce CCL22 through Tax and selectively interact with CCR4
+CD4
+ T cells, resulting in preferential 
transmission of HTLV-1 to CCR4
+CD4
+ T cells (Figure 5). In HTLV-1-seronegative healthy 
individuals, CD4
+CD25
+CCR4
+ T cell populations primarily consist of suppressive T cell subsets, such 
as Treg and Th2 cells [61]. However, as described above, cells of this T cell subset become Th1-like 
cells that overproduce IFN-γ in patients with HAM/TSP, while leukemogenesis develops and 
maintains the Foxp3
+ Treg phenotype in ATL patients (Figure 5).  Viruses 2011, 3                  
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Figure 5. Differential fate of HTLV-1-infected CD4
+CD25
+CCR4
+ T cells in HAM/TSP 
and ATL patients. After HTLV-1 infection, CD4
+CD25
+CCR4
+ T cells in HAM/TSP 
patients, which are primarily Th2 and Treg cells before infection, become IFN-γ
+Foxp3
– T 
cells (THAM cells) with high levels of intracellular HTLV-1 tax expression. In ATL patients, 
leukemogenesis develops and the Foxp3
+ Treg phenotype is maintained.  
 
 
To determine whether HTLV-1 expression contributes to the differential fate of HTLV-1-infected 
CD4
+CD25
+CCR4
+ T cells between HAM/TSP and ATL patients, differences in the HTLV-1 proviral 
load and the HTLV-1 tax mRNA and HTLV-1 HBZ mRNA expression of these populations were 
analyzed (Figure 6). Although HTLV-1 tax mRNA expression in CD4
+CD25
+CCR4
+ T cells was 
found to be significantly higher in HAM/TSP patients than in ATL patients, HTLV-1 proviral DNA 
loads and HBZ mRNA expression levels were found to be equivalent in the two groups [54] (Figure 6). 
This high HTLV-1 Tax expression in HAM/TSP CD4
+CD25
+CCR4
+ T cells (Foxp3
–) and low HTLV-1 
Tax expression in ATL CD4
+CD25
+CCR4
+ T cells (Foxp3
+) suggests that intracellular HTLV-1 
expression may act as a “switch” that directs T cell plasticity from Foxp3
+ Treg cells to IFN-γ
+Foxp3
– 
T cells. Indeed, a recent report highlighted that loss of Foxp3 in Treg cells and acquisition of IFN-γ 
may result in conversion of suppressor T cells into highly autoaggressive lymphocytes (exFoxp3
+ 
cells), which can contribute to the development of autoimmune conditions [62,63]. These findings 
support the hypothesis that HTLV-1 tax may be one of the exogenous retrovirus genes responsible for 
immune dysregulation through its interference in the equilibrium between inflammation and tolerance. Viruses 2011, 3                  
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This hypothesis is currently being tested as a means of elucidating the precise molecular mechanisms 
by which HTLV-1 influences the fate and function of CD4
+CD25
+CCR4
+ T cells, especially Foxp3
+ 
Treg cells. Further research investigating this hypothesis using animal models is required, as is further 
work to pathologically identify the exFoxp3
+ cells in the spinal cord lesions of HAM/TSP patients. 
Figure 6. Increased HTLV-1 tax mRNA expression in CD4
+CD25
+CCR4
+ T cells in 
HAM/TSP patients. The HTLV-1 proviral load in CD4
+CD25
+CCR4
+ T cells from 
HAM/TSP and ATL patients was quantified by real-time PCR (left panel, n = 3). 
Expression levels of HTLV-1 tax mRNA (center panel, HAM/TSP: n = 4, ATL: n = 3) and 
HBZ mRNA (right panel, n = 5) in CD4
+CD25
+CCR4
+ T cells from HAM/TSP and ATL 
patients were quantified by real-time RT-PCR. Data are presented as mean ± standard error. 
 
 
7. Mechanisms Underlying Increased HTLV-1 Tax Expression in HAM/TSP Patients 
As described above, higher levels of HTLV-1 Tax expression have been observed in HAM/TSP 
patients [11], and a correlation between Tax expression and disease risk [64] has been identified. Both 
findings, together with experimental evidence [65] and theoretical justification [66] for selective 
proliferation of HTLV-1 expressing T cells in vivo, indicate that increased HTLV-1 provirus 
expression may play an important role in the pathogenesis of HAM/TSP. However, the molecular 
mechanisms underlying the increased levels of HTLV-1 provirus expression in HAM/TSP patients are 
not understood. Evidence continues to accumulate that the genomic integration site of HTLV-1 
provirus affects the level of provirus expression. Continued accumulation of evidence is aided by the 
availability of the human genome sequence, which has enabled large-scale research into HTLV-1 
integration sites. This research has demonstrated that the provirus integration sites of HTLV-1 in vivo are 
not randomly distributed within the human genome but rather associated with transcriptionally active 
regions [67,68]; that the frequent integration into these transcription units is associated with increased 
levels of provirus expression; and, importantly, that the increased number of integration sites in Viruses 2011, 3                  
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transcription units is associated with HAM/TSP [68]. Future research should endeavor to elucidate the 
mechanisms underlying the immune dysregulation observed in HAM/TSP patients.  
8. Conclusion 
HTLV-1 initiates persistent infection of CD4
+ T cells and results in the development of HAM/TSP, 
a chronic neuroinflammatory disorder characterized by very high strong cellular and humoral immune 
responses. Because a higher viral load in HTLV-1-infected individuals increases the risk of HAM/TSP 
and is associated with high cellular and humoral immune responses, HTLV-1 infection-induced 
immune dysregulation may play an important role in the development and pathogenesis of this disease. 
The recent discovery of Treg cells has provided new opportunities for and generated increased interest 
in elucidating the mechanisms underlying the induction of immune activation by HTLV-1-infected T 
cells. Among the CD4
+ T helper cell populations that play a central role in adaptive immune responses, 
the CD4
+CD25
+CCR4
+ T cell population, which primarily consists of suppressive T cell subsets, such 
as the Treg and Th2 subsets, in healthy individuals, is the predominant viral reservoir of HTLV-1 in 
both ATL and HAM/TSP patients. Interestingly, cells of this T cell subset become Th1-like cells, 
overproducing IFN-γ in HAM/TSP patients, while leukemogenesis develops and maintains the Foxp3
+ 
Treg phenotype in ATL patients. These results indicate that HTLV-1 may intracellularly induce T cell 
plasticity from Treg to IFN-γ
+ T cells, which may contribute to the development of HAM/TSP. As 
such, these results support the hypothesis that HTLV-1 is one of the exogenous retrovirus genes 
responsible for immune dysregulation through its interference in the equilibrium maintained among 
host immune responses. Because the majority of immune disorders are of unknown etiology, the 
discovery of HTLV-1 and its association with inflammatory conditions has greatly enhanced our 
understanding of the pathogenic mechanisms underlying organ-specific immune disorders. Further 
investigation of the mechanism underlying HTLV-1 action in the immune system may result in 
identification of new molecular pathways that will further elucidate the basic mechanisms underlying 
immune-mediated disorders. 
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